Rationale: The Purkinje fiber network has been proposed as the source of arrhythmogenic Ca 2؉ release events in catecholaminergic polymorphic ventricular tachycardia (CPVT), yet evidence supporting this mechanism at the cellular level is lacking. 
the depolarizing impulse to the working myocytes of the ventricular myocardium. More than 40 years ago, Hoffman and colleagues proposed that PCs might "be a significant factor in human arrhythmias." 6 Since that time, substantial, but somewhat indirect, experimental data have accumulated supporting the concept that PCs play a key mechanistic role triggering a broad range of life-threatening ventricular arrhythmias. Indeed, recent optical mapping data of RyR2 R4496C/ϩ mutant mice, which to a remarkable extent phenocopy human CPVT, support the hypothesis that Ca 2ϩ -dependent arrhythmic triggers may be arising from the Purkinje fiber network. 7 A mechanistic basis for the proarrhythmic behavior of PCs is slowly emerging. Underlying ultrastructural features, such as a decreased T-tubular density, 8 the presence of IP 3 -sensitive Ca 2ϩ channels, 9 and susceptibility to Ca 2ϩ overload attributable to greater Na ϩ load, 10 may, in part, account for the propensity of these specialized cells to develop abnormal Ca 2ϩ release events. Moreover, recent data suggest that higher diastolic Ca i voltage coupling gain in Purkinje fibers may underlie the generation delayed afterdepolarizations (DADs) and triggered beats. 11 In addition to these cell-autonomous proarrhythmic properties, the macroscopic structural features of the specialized ventricular conduction system network may also contribute to the enhanced capacity of PCs to trigger arrhythmias. Whereas electric loading will normally prevent spontaneous Ca 2ϩ release events (SCaEs) in ventricular myocytes (VMs) from evoking propagated action potentials, the same is not true of events arising within PCs. Electrotonic interactions between PCs and the underlying myocardium at Purkinje-ventricular junctions are limited, such that stochastic Ca 2ϩ release events in PCs may trigger APs that successfully propagate into working myocytes. [12] [13] [14] Moreover, propagation across the Purkinje-ventricular junction is highly sensitive to the extent of coupling, as evidenced by a variety of experimental approaches, including computational studies and genetically engineered mouse model systems. 12, 15 As a consequence of these multiscale mechanisms, when challenged with stressors that promote electric remodeling or changes in intracellular Ca 2ϩ handling, such as mutations in Ca 2ϩ -handling proteins as seen in CPVT, PCs may be preferentially "primed" to develop arrhythmic triggers. 16 -22 Through a transcriptional screen, our laboratory recently identified a novel cell adhesion molecule named Cntn2, which is specifically expressed in cells of the specialized cardiac conduction system, including the distal Purkinje fiber network. 23 Moreover, we demonstrated that genetically engineered mice harboring a Cntn2-EGFP BAC transgene faithfully recapitulated expression of the endogenous protein, thereby providing a tool to specifically identify and distinguish PCs from working SCaEs. Interestingly, in our initial study, we found that even wild-type PCs were more arrhythmogenic than VMs, with more frequent unstimulated Ca i 2ϩ release events, DADs, and triggered beats. Using this same approach, we now have examined intracellular Ca 2ϩ dynamics in dissociated adult PCs and VMs from both wild-type and RyR2 R4496C/ϩ mutant mice, at baseline and following catecholaminergic stimulation, as might be seen during arrhythmic episodes in CPVT. We also determined the antiarrhythmic effects of RyR2 blockers in PCs and VMs from wild-type and mutant mice.
Methods
An expanded Methods section is available in the Online Data Supplement at http://circres.ahajournals.org.
Mutant Mice
All experiments were performed according to protocols approved by the New York University School of Medicine Institutional Animal Care and Use Committee and conformed to the NIH guidelines for the care and use of laboratory animals. Cntn2-EGFP BAC transgenic mice and RyR2 R4496C/ϩ mutant mice have both been described previously. 23, 24 All mice studied were F1 crosses between the 2 strains and used at 8 to 12 weeks of age. To minimize experimental variability, data from VMs and PCs from the same preparation were always collected on the same day.
Immunohistochemistry
Dissociated myocytes from adult hearts were stained as described previously. 23 Primary antibodies were directed again ankyrin-G, Scn5a, and ␣-actinin and visualized by confocal microscopy.
Ca

2؉ Imaging and Voltage Measurements
Adult myocytes were isolated using an established enzymatic digestion protocol, 25 and intracellular Ca 2ϩ imaging was performed using a microfluorimetry system (IonOptix Corp), as described previously. 23 SCaEs were defined as unstimulated increases in intracellular Ca 2ϩ and were quantified during the 6-second unpaced interval following the 10-beat pacing train. Transmembrane potential were recorded in whole-cell current-clamp mode (Axon Instruments), also as described previously. 23, 25 
Statistics
Kinetic parameters were compared using Student's t test. The proportion of cells displaying SCaEs was compared using Fisher's exact test. The number of SCaEs per cell was compared by the Mann-Whitney test. Probability values of PϽ0.05 were considered significant.
Results
Identification of Adult Murine PCs
We previously demonstrated that the Cntn2-EGFP BAC transgenic mouse strain could be used to specifically identify the relatively rare PCs from a mixed population of dissociated ventricular cells. 23 The PCs could be visualized both in situ, in the subendocardial region of the ventricles ( Figure 1A ), and in dissociated cells, where both VMs and PCs express the cardiac specific proteins Scn5a and sarcomeric ␣-actinin ( Figure 1B through 1E ), but only the PCs express EGFP. 
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Kinetic Properties in PCs and VMs
Fluorescence photometry with the calcium-sensitive dye x-Rhod-1 was used to study intracellular Ca 2ϩ dynamics ( Figure 2 ). Confirming our previous observation, 23 wild-type PCs displayed significantly slower kinetics of activation and relaxation compared to VMs, with rise times of 117Ϯ6.6 (nϭ8) versus 68Ϯ2.3 ms (nϭ10); PϽ0.00001; and decay of 225Ϯ24 (nϭ8) versus 155Ϯ10 ms (nϭ10); PϽ0.01. A similar large difference in kinetics was observed comparing the RyR R4496C/ϩ mutant PCs and mutant myocytes, with rise times of 129Ϯ6.5 (nϭ10) versus 71Ϯ5.4 ms (nϭ10); PϽ0.000002; and decay of 312Ϯ23 (nϭ10) versus 201Ϯ15 ms (nϭ10); PϽ0.001. Interestingly, the decay in the mutant PCs was significantly longer than in wild-type PCs (PϽ0.01).
SCaEs in RyR R4496C/؉ PCs
We next determined the propensity of VMs and PCs to develop SCaEs following field stimulation at a range of pacing frequencies. We first examined wild-type VMs and PCs. As expected, wild-type VMs were quite stable; none of 15 cells studies developed SCaEs at 1 Hz, and only 1 cell displayed unpaced SCaEs after pacing at 3 or 5 Hz. Wild-type PCs had a greater tendency to develop unpaced SCaEs compared to the VMs, especially following higher pacing frequencies (3 of 10 cells at 3 and 5 Hz), as shown in Figure  3 . We next examined the behavior of cells from RyR R4496C/ϩ mutant mice. Mutant VMs and mutant PCs were more arrhythmogenic than their wild-type counterparts, both with respect to the proportion of cells displaying SCaEs and the number of SCaEs per cell. This was especially the case for the RyR R4496C/ϩ mutant PCs, with as many as 62% of cells studied showing arrhythmic activity, as shown in Figure 3 and summarized in Table 1 .
Increased Sensitivity to Catecholaminergic Stimulation
Inasmuch as arrhythmic behavior in patients and animal models of CPVT is provoked during catecholaminergic stimulation, the effects of isoproterenol treatment (30 nmol/L) on intracellular Ca 2ϩ dynamics in wild-type and mutant VMs and PCs was assessed. When paced at 1 Hz, wild-type VMs, wild-type PCs, and mutant VMs all showed modest increases in the proportion of cells that developed SCaEs compared to untreated controls, as shown in Figure 4 and Table 1 . However, the effect was most profound in mutant PCs; almost all (90%; 9 of 10) developed arrhythmogenic Ca 2ϩ activity. Moreover, the quantity of SCaEs per cell was significantly greater for the RyR2 R4496C PCs (12.2Ϯ1.5/cell) compared to RyR2 R4496C VMs (1.1Ϯ0.48/cell). Furthermore, even at the slow pacing frequency of 1 Hz, the PCs developed marked abnormalities in intracellular Ca 2ϩ handling, including oscillations, alternans, and sustained salvos of presumed triggered beats following the end of the pacing train ( Figure  4D through 4G) . To confirm that these abnormalities in calcium regulation were indeed sufficient to trigger action potentials, we performed simultaneous Ca 2ϩ imaging and recordings of transmembrane potentials in whole-cell currentclamp mode. These studies indeed demonstrated that SCaEs could successfully trigger action potentials in the mutant PCs ( Figure 4H) . Thus, the RyR R4496C/ϩ mutant PCs appeared to be especially sensitive to the proarrhythmic effects of catecholaminergic stimulation.
Preferential Suppression of SCaEs in Mutant PCs
The antiarrhythmic agent flecainide has shown efficacy in preventing ventricular arrhythmias in mice and humans with Casq2-associated CPVT. 26 We therefore tested the effects of flecainide on the magnitude of SCaEs in VMs and PCs. In agreement with previous studies, 27 the modest arrhythmic activity observed in wild-type VMs was diminished with flecainide, both with respect to the number of cells developing SCaEs and the number of SCaEs per cell. We also observed efficacy in wild-type PCs from these same hearts, as shown in Figure 5 and Table 2 . As expected, cells from RyR2 R4496C/ϩ mutant mice were substantially more arrhythmic at baseline than their wild-type counterparts. Surprisingly, however, the mutant VMs appeared resistant to the antiarrhythmic effects of flecainide, whereas the mutant PCs showed a significant reduction in the number of cells with SCaEs, as well as a reduction in SCaEs per cell, as shown in Figure 5B and 5D. We also tested the effects of tetracaine, which preferentially reduces RyR2 open probability. 28 In contrast to flecainide, this agent suppressed SCaEs in mutant PCs and VMs with equal efficacy, as shown in Figure 5E and 5F. These data are summarized in Table 2 .
Discussion
Recent data suggest that SR Ca 2ϩ -release channels comprised of the CPVT-causing RyR2 R4496C mutant protein display increased sensitivity to both cytosolic and luminal Ca 2ϩ , predisposing them to the development of arrhythmogenic DADs and triggered beats. 29 -32 In this study, we show that PCs from mice harboring this same mutation are preferentially and exquisitely sensitive to this underlying molecular defect. Compared to genetically identical VMs, the mutant PCs show more profound abnormalities in intracellular Ca 2ϩ handling, including the development of SCaEs at baseline and, as demonstrated by simultaneous calcium and voltage measurements, the progression to triggered beats in response to relatively modest catecholaminergic stimulation.
This study extends our prior observation indicating that even wild-type PCs are more likely to develop DADs and triggered beats compared to VMs. 23 The basis for this heightened proclivity of PCs to develop arrhythmic behavior is not fully known, although the diminished T-tubular density, 8 altered action potential morphology, 33 altered kinetics of Ca 2ϩ handling (Figure 2) , and increased intracellular Na ϩ load 10 may all be contributory factors. In addition, the participation of IP 3 -sensitive Ca 2ϩ channels as part of the excitation-contraction coupling machinery may also influence this arrhythmogenic behavior. 9 As such, when confronted with another perturbation, in this case, a defective intracellular Ca voltage coupling gain, behavior which may be due in part to diminished inwardly rectifying potassium currents (I K1 ). 11 Furthermore, in contrast to well-coupled and electrically loaded working myocytes, in PCs, oscillations in membrane potential are uniquely capable of evoking propagated action potentials that can traverse the Purkinje-ventricular junction into the myocardium proper. 12 Our analysis of myocytes from RyR2 R4496C mutant mice strongly support the recent suggestion that the Purkinje network may serve as the arrhythmogenic trigger in CPVT associated with RyR2 mutations. This initial hypothesis was based, in part, on the characteristic bidirectional ventricular tachycardia seen in patients and mice with this syndrome 24, 34 and data demonstrating that ablation of the right ventricular subendocardium (where Purkinje fibers are found) with Lugol's solution converted the biventricular tachycardia to a monomorphic arrhythmia. 7 Whether or not PCs serve as arrhythmic triggers in CPVT associated with mutations in the calsequestrin gene remains to be seen, 35, 36 but comparable studies in Casq2 mutant mice should be informative. More broadly, the Purkinje fiber network has been implicated in the initiation of ventricular tachycardia not only in CPVT but also following myocardial infarction, in dilated cardiomyopathies, in idiopathic ventricular fibrillation, in postshock arrhythmias, and other inherited channelopathies including Brugada and long QT syndromes. 7, [37] [38] [39] [40] [41] [42] A similar analysis of PC behavior at the cellular level of resolution in these diseases should be equally revealing.
Several experimental and clinically approved agents have recently been shown to inhibit arrhythmogenic Ca 2ϩ waves. 26, 27, 43 In particular, the class 1C antiarrhythmic agent flecainide was shown to inhibit RyR2 channel activity by reducing the duration of channel openings, especially when the RyR2 channel was activated by high luminal Ca 2ϩ concentration. Moreover, flecainide showed efficacy in preventing ventricular arrhythmias in mice and in humans with Casq2-associated CPVT. 26 Here, we show that flecainide is indeed effective in suppressing SCaEs not only in VMs but also in PCs. Unexpectedly, however, whereas flecainide appears equally efficacious in VMs and PCs from wild-type mice, in RyR2 R4496C/ϩ mutant mice, the beneficial effect appears restricted to only the PCs. The suppressive effect we observed in PCs occurs at substantially lower concentrations than the reported IC 50 for inhibition of RyR2 open probability. 27 Conceivably, flecainide may be acting through additional targets such as voltage-gated sodium channels, secondarily influencing intracellular Ca 2ϩ load and the propensity for arrhythmogenic SCaEs. Interestingly, we have recently found that Na v 1.8/Scn10a is preferentially expressed in PCs, which could account for the differential sensitivity of these cells to flecainide compared to VMs. Indeed, with the more pure RyR2 inhibitor tetracaine, we observed equal efficacy suppressing SCaEs in both VMs and PCs. Accordingly, it will be particularly informative to see whether flecainide has clinical utility not only in Casq2-associated CPVT but also in RyR2-dependent forms of this syndrome. This study was facilitated by our recent discovery of Cntn2 in the specialized conduction system and the recognition that Cntn2-EGFP mice could facilitate the identification and isolation of conduction system cells, including PCs. 23 This approach is similar in principal to using Cx40-EGFP knock-in mice, 44 although that strategy may be less specific, because Cx40 is expressed not only in the conduction system but also in atrial myocytes and vascular endothelium and smooth muscle cells. 45 In summary, our study provides compelling evidence at the cellular level that the Purkinje fiber network is a critical contributor to arrhythmia initiation in CPVT and that defects in intracellular Ca 2ϩ regulation underlie the disease phenotype. These data add to an accumulating body of literature suggesting that the unique structural and functional properties of PCs and the network they comprise play a mechanistic role in a broad range of arrhythmic syndromes. Moreover, our data provide impetus for focusing on PCs as specific antiarrhythmic targets. 
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